SecBot SecBot

INAB

IN8BIO, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001740279 Biotech & Drug Discovery
$0.9655 −0.08 (−8.05%)
Oct 26 4:00 PM ET · prev $1.05
Market cap
$9.7M
Nano cap
Median target
$6.00
+521% · range $5.00–10.00
Next earnings
Nov 4
in 9 days · EPS est. −$0.34
1 year
−54.0%
from $2.10 · Oct 27
30 days
−22.1%
from $1.24
52-week range
$0.9600–2.59
−63% from high · low Aug 3
Avg volume 20D
46.1K
Oct 26 spike 183.1K
Short interest
46.4K
≈0.5% of shares · −26.4%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read BEARISH 5 reports · latest
Balance 3 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next Earnings date, Nov 4, 2026
Strongest BEARISH IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to $2.8M…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.225 → −$0.337 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −26.4% to 46.4K shares. 1.0 days to cover, ≈0.5% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT1$1.00
GEODE CAPITAL MANAGEMENT, LLCDOUBLED86,239$127.6K
CAPTRUST FINANCIAL ADVISORSADD33,295$49.3K
JONES FINANCIAL COMPANIES LLLPTRIM768$1.1K
UBS Group AGTRIM480$710.00
Alyeska Investment Group, L.P.DOUBLED957,484$2.2M
FRANKLIN RESOURCES INCDOUBLED914,531$2.0M
VANGUARD GROUP INCTRIM28,348$66.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 3 analysts

Price is below the lowest target. Median implies +521%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Mar 13, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 14, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Feb 12, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Feb 11, 2025Jones Trading
UPGRADE
UPGRADEBuy
Nov 26, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Nov 13, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
May 27, 2026
FAIRBAIRN EMILY
Director
GIFT724,637 sh
May 9, 2026
Epperly Corinne
Director
AWARD22,000 sh
May 9, 2026
Greenwood Luba
Director
AWARD22,000 sh
May 9, 2026
Ho William Tai-Wei
CEO
AWARD154,500 sh
May 9, 2026
Lamb Lawrence
EVP and CSO
AWARD54,000 sh
May 9, 2026
FAIRBAIRN EMILY
Director
AWARD22,000 sh
May 9, 2026
McCall Patrick
CHIEF FINANCIAL OFFICER
AWARD56,250 sh
May 9, 2026
Rochlin Kate
President and COO
AWARD60,000 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$0.34
EPS estimate, this quarter
−50%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.34-$0.57–-$0.22+11.4%$0.00
Next Q-$0.35-$0.65–-$0.17+11.8%$0.00
Current FY-$1.11-$1.49–-$0.89-2.4%$0.00
Next FY-$0.95-$1.24–-$0.64+1.6%$1.1M

Short side

FINRA· Sep 30, 2026
46,440
shares short
-26.4%
vs prior settlement
1.0
days to cover
≈0.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 22, 2026 Other
IN8bio to Present at Sidoti Small-Cap Virtual Conference
IN8bio to Present at Sidoti Small-Cap Virtual Conference
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
1 shares ($1.00)
Jun 3, 2026 Press
IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting…
Impact 3/10
Jun 1, 2026 SEC
IN8bio entered into an at-the-market (ATM) equity offering agreement with JonesTrading to sell up to $2.8M of common…
8-K — Impact 6/10
Jun 1, 2026 SEC
IN8bio filed a 424B5 prospectus supplement establishing an at-the-market (ATM) equity offering facility with…
424B5 — Impact 6/10
May 27, 2026 Insider
FAIRBAIRN EMILY gifted 724,637 shares
Director
May 18, 2026 SEC
IN8bio filed Amendment No. 1 to its existing S-3 shelf registration, maintaining the $200M aggregate offering capacity…
S-3/A — Impact 7/10
May 9, 2026 Insider
Epperly Corinne was granted 22,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
INAB Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Sep 22, 2026
Press release
IN8bio to Present at Sidoti Small-Cap Virtual Conference
IN8bio to Present at Sidoti Small-Cap Virtual Conference
Aug 10, 2026
Press release
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 6, 2026
Earnings
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 5, 2026
Earnings date
INAB Q2 2026 Earnings Scheduled — 2026-08-05
Jul 9, 2026
Press release
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles PFS in Newly Diagnosed Glioblastoma

SecBot reports

5 filings · 2 press releases · 0 bullish · 3 bearish · 2 neutral
All INAB filing & press-release reports (7)